Compare ADMA Biologics Inc (ADMA) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Expedia Group Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Expedia Group Inc trades at $260.31 (market cap $32.39B). The key difference: Expedia Group Inc is far larger — about 15.2× ADMA Biologics Inc's market cap, and Expedia Group Inc pays a 0.65% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EXPE | |
|---|---|---|
Market Cap | $2.13B | $32.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $301.31 |
52-Week Low | $7.60 | $176.09 |
Enterprise Value | $2.20B | $31.30B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Expedia Group (EXPE) trades at $269.87, up 0.44% with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported consistent earnings beats in recent quarters with Q1 2026 EPS of $1.96 exceeding expectations of $1.41. Revenue growth has been steady, climbing from $11.7B in 2022 to $14.7B in 2025, while maintaining robust profitability with a 90.27% gross margin. Recent developments include the CarTrawler acquisition and positive travel industry research positioning the company for continued growth.
EXPE presents a compelling investment case with analyst consensus price target of $281.75 representing 4.4% upside potential. The stock offers exposure to the resilient travel sector with improving operational efficiency and strong cash flow generation. Key risks include travel sector volatility and competitive pressures, but the company's technological innovation and market position provide defensive characteristics in the evolving travel landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
